Lung Cancer Screening Market Size:
The Lung Cancer Screening Market was valued at USD 3.66 billion in 2024 and is expected to reach USD 7.44 billion by 2032, growing at a CAGR of 9.32% over the forecast period of 2025-2032.
To Get more information on Lung Cancer Screening Market - Request Free Sample Report
The global lung cancer screening market is growing rapidly, driven by factors such as the increasing incidence of lung cancer, growing awareness, growth in the aging population, and the adoption of low-dose CT scans as a screening test. As lung cancer is the most lethal type of cancer globally, governments and health agencies are encouraged to focus on extensive screening, especially among high-risk populations. There are technological improvements, mobile screening units, and AI-imaging tools that will add to the lung cancer screening market growth.
The U.S. lung cancer screening market size was valued at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, growing at a CAGR of 8.89% over the forecast period of 2025-2032.
AstraZeneca and Qure recently reported on the implementation of AI in a new paper. Announced the processing of more than 5 million AI-powered chest X-rays across 20+ countries, proving scalability and accelerating adoption into clinical screening workflow.
The North American lung cancer screening market is witnessing a domination from the U.S. on account of widespread acceptance of low-dose computed tomography (LDCT) screening, clear payment policies, and developed healthcare infrastructure. Clear national screening guidelines, public awareness campaigns, and early introduction of screening programmes also contribute to its leadership role. Moreover, ongoing improvements in diagnostics and governmental initiatives for broader availability also ensure that it continues to be a leading market in the region.
In the United States, the American Cancer Society Cancer Facts & Figures 2025 estimates more than 2 million new cancer diagnoses in 2025, and lung cancer will comprise ~11–12% of those cases.
Lung Cancer Screening Market Dynamics:
Drivers
-
High Incidence of Lung Cancer is Propelling Market Growth
Lung cancer is highly diagnosed and a major cause of cancer-related deaths globally. Due to the diagnostic delay in later stages, since many are asymptomatic, rigorous screening is required for the early detection and prevention of lung cancer. The increasing incidence, mainly among high-risk populations such as chronic tobacco smokers and the aging population, has increased the urgent need for screening programs. The proliferating patient demographic has necessitated health systems to invest in lung cancer screening infrastructure, hence boosting the industry prospects.
In 2020, it was estimated that there would be around 2.2 million new cases (11.4% of the total number of cases) and 1.8 million deaths (18.4% of the total number of deaths) of lung cancer worldwide, and it is expected that by 2035, deaths will increase to nearly 3 million.
The National Cancer Institute reports a persistent decrease in lung cancer incidence and lung cancer-related mortality from 2018 to 2022: Men declined by 3.5% and women by 3.4% annually, demonstrating that prevention, early detection, or treatment can make a substantial difference.
-
Rising Screening Technologies are Driving the Market Growth
The effectiveness, efficiency, and availability of lung cancer screening have been greatly improved by technological advances. Since the advent of low-dose computed tomography (LDCT), early detection has taken a new turn in that smaller nodules in the lungs are being identified with less radiation dose. Furthermore, new tools, such as AI image analysis and biomarker-based liquid biopsies, are reducing false positives and increasing diagnostic confidence. These advances are helping to drive the increased attractiveness of lung cancer screening to both physicians and patients, driving uptake and market growth.
A meta-analysis and review published in Nature Oncology found that AI-augmented LDCT tools have a high diagnostic performance—94.6% sensitivity and 93.6% specificity, demonstrating how AI is elevating the level of screening accuracy while also trimming down the number of false positives and negatives.
At the 2025 ATS International Conference, a deep-learning model that analyzed LDCT scans of more than 21,000 subjects performed with impressive AUC scores (86% after 1 yr and 79% after 6 yr) and could even predict cancer risk in never-smokers, signaling a transition toward personalized predictive screening approaches
Restraint
-
High Cost of Screening Technologies is Hampering the Market from Growing
Penetration is also limited by the high price of advanced lung cancer screening technology, especially low-dose computed tomography (LDCT) and biomarker-based testing. These technologies call for sophisticated imaging systems, skilled radiologists, and sometimes specialized infrastructure with large funding and operational costs.
Moreover, patients could have to bear the personal cost for post-screening diagnostics after first-line screenings, exacerbating the cost burden. This impediment is particularly conspicuous in low‐ and middle‐income countries where health care budgets are restricted and health insurance coverage for cancer early detection is poor, or simply nonexistent. Accordingly, early detection is limited, and lung cancer screening programs are not widely adopted.
Lung Cancer Screening Market Segmentation Analysis:
By Type of Test / Modality
Low-dose computed tomography (LDCT) segment dominated the lung cancer screening market share with a 61.25% in 2024 on account of being a successful diagnostic alternative for early detection of lung cancer among at-risk individuals, including heavy, long-term smokers. LDCT is far more sensitive in detecting small nodules and abnormalities than conventional chest X-ray, and has been widely included in clinical guidelines and in national screening programs, in developed regions, such as the U.S. and some European countries. Its potential to lower the rate of death from lung cancer with early detection has earned it the favor of the provider community.
The biomarker-based tests segment is expected to grow at the highest CAGR during the forecast period, due to continuous developments in precision medicine and molecular diagnostics. These tests provide an opportunity for non-invasive early detection of lung cancer because they would detect genetic, proteomic, or epigenetic markers in blood, sputum, or other biological fluids. The growing popularity of personalized therapeutic decision-making processes, the rise in research funding, along the introduction of liquid biopsies in diagnostic regimes are driving the adoption of biomarker-based screening.
By Cancer Type
The non-small cell lung cancer (NSCLC) segment led the lung cancer screening market in 2024 with around 84.15% market share, since it is the most common type of lung cancer among all lung cancers. NSCLC tends to grow more slowly than small cell lung cancer, so there may be more time to find it with a screening test like LDCT. From a clinical perspective, NSCLC screening in high-risk populations is the main focus of CPG worldwide, which has the potential to increase demand for screening programs, especially dedicated to finding NSCLC. Public declared awareness programs and screening-driven targeting activities have further reflected its dominant market share.
The NSCLC is the fastest-growing segment lung cancer screening market growth is also anticipated over the forecast period, attributed to improved diagnostics capabilities, growing commitment to early detection approaches, and greater access to targeted drugs. The combination of molecular diagnostics and biomarker-based screening helps to improve the accuracy of early detection of NSCLC, and the continued development of targeted therapies will promote the advancement of precision oncology. Furthermore, the healthcare policies in most countries are providing a broader range of screening services, especially for the patients at risk, which in turn is increasing the development and progression of the NSCLC screening market.
By Age Group
The lung cancer screening market, based on age, was led by the 60–69 years segment in 2024, owing to higher risk populations in global clinical lung screening programs. People of this age group generally have a long history of cigarette and other carcinogenic exposure, resulting in a high risk of lung cancer. This population is often the subject of screening schedules in the healthcare system and among the insured by LDCT, so that they have a higher screening rate. Moreover, this segment is active in preventive health care programs, which also favours its strong position on the market.
The age group 50–59 years is anticipated to be the fastest growing segment over the forecast period, with a rising trend of early screening and a change in screening guidelines by healthcare organizations. A considerable body of evidence suggests that there may be a benefit in the early detection of lung cancer even before the usual age limit of 60+ years, especially in lung cancer patients who are smokers or have a history of occupational exposure. With the growing trend toward early detection and an increasing awareness of preventive health among 50-somethings, this group is increasingly screening regularly, driving fast growth in the market.
By End User
The lung cancer screening market is categorised into hospitals, diagnostic centres, and specialty clinics, and the hospitals segment led the market in 2024 on account of their established infrastructure, advanced imaging modalities such as LDCT, and experienced healthcare professionals. It is common that in hospitals, the first referral and diagnosis of patients under cancer screening occurs, and has more patients' confidence and an easier follow-up of the care. In addition, screenings have been reimbursed by government and private insurance programs when carried out in hospital settings, augmenting the stature of hospitals in organized lung cancer screening.
Among these, the 'others' segment (such as mobile screening units, NGOs, and community health programs) will witness the highest growth during the predicted period. This is a reflection of a growing number of initiatives designed to enhance delivery in underserved and remote communities where conventional healthcare infrastructure is sparse. There is an increasing number of mobile units and outreach services globally, particularly, low and middle-income areas, to close the gap in lung cancer identification. Flexible, community-based approaches such as these are low-cost and easily up-scaled, leading to fast market penetration.
Lung Cancer Screening Market Regional Insights:
North America dominated the lung cancer screening market trend in 2024, with around 40.3% market share due to the presence of developed healthcare infrastructure, early LDCT screening adoption, and high reimbursement support from the government and private payers. In the US, the USPSTF recommendation and Medicare LDCT coverage have increased screening uptake substantially. Rise in awareness among healthcare professionals and the general population on early detection of lung cancer, leading players, and advancement of technologies in tracking devices in the screening process are propelling the market.
The Asia Pacific region is projected to register the highest growth rate in the lung cancer screening market analysis, with around 9.94% CAGR during the forecast period, primarily due to the increasing incidence of lung cancer, the growing healthcare expenditure, and the increasing focus of governments on early detection and prevention. China, Japan, and South Korea have initiated mass screening programs to tackle the unprecedented load of lung cancer. Growth of the market in the region is further driven by improvements in levels of healthcare access, growing use of AI-based diagnostic tools, and a rise in insurance coverage across the region. Furthermore, increasing awareness and public health programs are promoting patient enrolment in the screening, which is boosting the market growth in the Asia Pacific.
The lung cancer screening market in Europe is projected to expand at a significant CAGR, propelled by growing emphasis on preventive healthcare, high prevalence of lung cancer, and surge in use of various advanced screening methods such as low-dose computed tomography (LDCT). Many countries in the region have made serious progress in, or scaled up, the national lung cancer screening programmes (e.g., Germany, the UK, France, the Czech Republic, and Poland). By sponsored programs, pilot projects, and innovation in diagnostic imaging, the early detection power is evolving, thereby promoting market growth in the region.
Latin America is expected to grow at a steady pace for the lung cancer screening market analysis on account of increasing prevalence of lung cancer, increasing awareness, and slowly accepting new screening technologies such as low-dose computed tomography (LDCT) and liquid biopsies. Nevertheless, the region still experiences significant challenges such as poor health care infrastructure, expensive screening, and poor adaptation of the national screening programme.
The lung cancer screening market in the Middle East & Africa (MEA) is also witnessing significant growth due to advances in access to health care and the increasing knowledge of early cancer detection, which has contributed to the slow uptake of lung cancer screening programs. However, challenges including low awareness in the public, poor access to advanced diagnostics technologies, and a lack of organized screening programs in many countries still restrict market take-off. With these challenges, the market is set to grow steadily on the basis of heightened government commitment to managing non-communicable diseases.
Get Customized Report as per Your Business Requirement - Enquiry Now
Lung Cancer Screening Market Key Players:
The lung cancer screening market companies are GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Samsung Medison Co., Ltd., Carestream Health, Shimadzu Corporation, Vuno Inc., Zebra Medical Vision, Qure.ai, Aidoc, Riverain Technologies, Lunit Inc., Roche Diagnostics, Illumina, Inc., Guardant Health, Exact Sciences Corporation, Bio-Rad Laboratories, CT Screening International, and other players.
Recent Developments in the Lung Cancer Screening Market:
-
Jan 2024, GE HealthCare partners with Optellum to roll out the Virtual Nodule Clinic—a computer vision-based solution that interprets CT lung scans and gives each nodule an associated cancer-risk score, allowing for quicker and more accurate detection of nodules that may be malignant.
-
Nov 2023, Philips partnered with Roswell Park Comprehensive Cancer Center to introduce "Project Eddy" in Buffalo, New York, sending out mobile units with Philips Incisive CT scanners. The initiative importantly targets at-risk populations like firefighters, said to be approximately 60% more likely to get lung cancer due to occupational hazards.
Report Attributes Details Market Size in 2024 USD 3.66 Billion Market Size by 2032 USD 7.44 Billion CAGR CAGR of 9.32% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Type of Test / Modality (Low-Dose Computed Tomography (LDCT), Chest X-ray, Sputum Cytology, Biomarker-based Tests, Others (e.g., PET scans, MRI))
• By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
• By Age Group (40–49 years, 50–59 years, 60–69 years, 70+ years)
• By End User (Hospitals, Diagnostic Centers, Cancer Research Institutes, Ambulatory Surgical Centers (ASCs), Others (mobile screening units, NGOs, etc.))Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Samsung Medison Co., Ltd., Carestream Health, Shimadzu Corporation, Vuno Inc., Zebra Medical Vision, Qure.ai, Aidoc, Riverain Technologies, Lunit Inc., Roche Diagnostics, Illumina, Inc., Guardant Health, Exact Sciences Corporation, Bio-Rad Laboratories, CT Screening International, and other players.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Application
2.3.2 Market Size By Ownership
2.3.2 Market Size By Center Type
2.3.2 Market Size By Services
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Screening Uptake and Eligibility Trends (2024)
4.1.1 Percentage of eligible individuals undergoing screening, by region
4.1.2 Growth in screening adherence among high-risk populations (age, smoking history)
4.1.3 Expansion in the screening pool due to updated clinical guidelines (USPSTF, NCCN, etc.)
4.2 Modality Usage Distribution (2024)
4.2.1 Market share of screening modalities (LDCT, Chest X-ray, Sputum Cytology, Biomarker-based, Others)
4.2.2 Annual growth rates for advanced and emerging screening tests
4.2.3 Diagnostic performance metrics (sensitivity/specificity) by test modality
4.3 Lung Cancer Detection Rates by Stage and Modality (2024)
4.3.1 Early vs. late-stage detection trends by screening method
4.3.2 Comparative NSCLC and SCLC detection statistics
4.3.3 Screening effectiveness in reducing mortality and disease burden
4.4 Regional Screening Program Penetration (2020–2032)
4.4.1 Government-led lung cancer screening programs and coverage
4.4.2 Role of NGOs, public-private partnerships, and rural outreach
4.4.3 Volume of mobile screening units and community-based deployments
4.5 Economic Burden Avoidance and Cost Savings through Screening (2024)
4.5.1 Cost savings from early diagnosis and treatment deferral
4.5.2 Comparative cost-per-diagnosis by test type
4.5.3 Cost-effectiveness of national and regional screening strategies
4.6 AI & Software Integration Trends (2024–2030)
4.6.1 Penetration of AI-assisted interpretation in LDCT and radiology workflows
4.6.2 Impact of AI tools on false positives/negatives and workflow efficiency
4.6.3 Regional reimbursement landscape for AI-enabled screening tools
5. Lung Cancer Screening Market Segmental Analysis & Forecast, Type of Test / Modality, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Low-Dose Computed Tomography (LDCT)
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Chest X-ray
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Sputum Cytology
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Biomarker-based Tests
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
5.6 Others (e.g., PET scans, MRI)
5.6.1 Key Trends
5.6.2 Market Size & Forecast, 2021 – 2032
6. Lung Cancer Screening Market Segmental Analysis & Forecast, By Cancer Type, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Small Cell Lung Cancer (SCLC)
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
7. Lung Cancer Screening Market Segmental Analysis & Forecast, By Age Group, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 40–49 years
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 50–59 years
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 60–69 years
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 70+ years
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
8. Lung Cancer Screening Market Segmental Analysis & Forecast, By End User, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Hospitals
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Diagnostic Centers
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Cancer Research Institutes
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
8.5 Ambulatory Surgical Centers (ASCs)
8.5.1 Key Trends
8.5.2 Market Size & Forecast, 2021 – 2032
8.6 Others (mobile screening units, NGOs, etc.)
8.6.1 Key Trends
8.6.2 Market Size & Forecast, 2021 – 2032
9. Lung Cancer Screening Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.2.3 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.2.4 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.2.5 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.2.6 Lung Cancer Screening Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.2.6.1.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.2.6.1.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.2.6.1.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.2.6.2.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.2.6.2.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.2.6.2.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.3 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.4 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.5 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6 Lung Cancer Screening Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.1.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.1.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.1.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.2.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.2.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.2.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.3.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.3.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.3.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.4.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.4.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.4.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.5.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.5.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.5.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.6.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.6.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.6.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.7.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.7.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.7.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.3.6.8.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.3.6.8.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.3.6.8.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.3 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.4 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.5 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6 Lung Cancer Screening Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.1.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.1.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.1.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.2.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.2.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.2.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.3.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.3.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.3.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.4.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.4.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.4.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.5.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.5.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.5.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.6.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.6.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.6.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.4.6.7.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.4.6.7.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.4.6.7.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.3 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.4 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.5 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5.6 Lung Cancer Screening Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.6.1.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.6.1.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.6.1.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.6.2.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.6.2.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.6.2.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.6.3.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.6.3.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.6.3.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.6.4.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.6.4.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.6.4.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.5.6.5.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.5.6.5.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.5.6.5.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.3 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.4 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.5 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6 Lung Cancer Screening Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.1.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.1.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.1.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.2.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.2.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.2.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.3.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.3.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.3.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.4.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.4.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.4.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.5.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.5.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.5.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Lung Cancer Screening Market Size & Forecast, By Type of Test / Modality, 2021 – 2032
9.6.6.6.2 Lung Cancer Screening Market Size & Forecast, By Cancer Type, 2021 – 2032
9.6.6.6.3 Lung Cancer Screening Market Size & Forecast, By Age Group, 2021 – 2032
9.6.6.6.4 Lung Cancer Screening Market Size & Forecast, By End User, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 GE HealthCare
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Siemens Healthineers
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Philips Healthcare
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 Canon Medical Systems Corporation
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 Fujifilm Holdings Corporation
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Samsung Medison Co., Ltd.
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 Carestream Health
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 Shimadzu Corporation
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 Vuno Inc.
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 Zebra Medical Vision
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Qure.ai
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Aidoc
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 Riverain Technologies
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Lunit Inc.
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 Roche Diagnostics
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 Illumina, Inc.
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 Guardant Health
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 Exact Sciences Corporation
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 Bio-Rad Laboratories
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 CT Screening International
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Market Segments:
By Type of Test / Modality
- Low-Dose Computed Tomography (LDCT)
- Chest X-ray
- Sputum Cytology
- Biomarker-based Tests
- Others (e.g., PET scans, MRI)
By Cancer Type
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
By Age Group
- 40–49 years
- 50–59 years
- 60–69 years
- 70+ years
By End User
- Hospitals
- Diagnostic Centers
- Cancer Research Institutes
- Ambulatory Surgical Centers (ASCs)
- Others (mobile screening units, NGOs, etc.)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
